myotubularin related protein 3Genealiases: FYVE-DSP1 · ZFYVE10
Q-omics provides the consensus-scored MTMR3 profile across patient tissues and cancer cell-line models. MTMR3 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTMR3 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, MTMR3 RNA expression shows 21,268 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where MTMR3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTMR3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTMR3 survival associations across molecular data types. MTMR3 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTMR3 RNA expression–survival associations across cancer types. High MTMR3 expression shows unfavorable associations in ACC and LIHC, but favorable associations in HNSC, ESCA, KIRC and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTMR3 RNA expression.
This table summarizes MTMR3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MTMR3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTMR3 shows lower tumor expression in COAD, UCEC, BRCA, KIRC and LUAD and higher tumor expression in LIHC. The COAD box plot shows higher MTMR3 RNA expression in normal versus tumor tissue (log2 FC = −0.540, t-test p < 0.001).
This table shows molecular features associated with MTMR3 in patient tissues and cancer cell lines. In patient samples, MTMR3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTMR3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
